Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain

Alternate title: 
J2 - Clin J Pain
Secondary title: 
T2 - Clinical journal of pain
Short title: 
Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain
Authors: 
Kanbayashi, Yuko
Hosokawa, Toyoshi
Okamoto, Kousuke
Fujimoto, Sawako
Konishi, Hideyuki
Otsuji, Eigo
Yoshikawa, Toshikazu
Takagi, Tatsuya
Miki, Tsuneharu
Taniwaki, Masafumi
Volume: 
27
Start page: 
664-7
Annotations: 
Type D, Priority 5
Date: 
Oct
Year: 
2011
Accession number: 
21471811
Database: 
MEDLINE Cohort
Number: 
M1 - 8
Serial: 
1536-5409
ID: 
12815
DOI: 
http://dx.doi.org/10.1097/AJP.0b013e3182168fed
Notes: 
N1 - Kanbayashi Y Hosokawa T Okamoto K Fujimoto S Konishi H Otsuji E Yoshikawa T Takagi T Miki T Taniwaki M
Key words: 
Administration, Cutaneous
Adolescent
Adult
Aged
Aged, 80 and over
*Analgesics, Opioid/ad [Administration & Dosage]
Analgesics, Opioid/ae [Adverse Effects]
Child
Female
*Fentanyl/ad [Administration & Dosage]
Humans
Logistic Models
Male
Middle Aged
Morphine/ae [Adverse Effects]
Neoplasms/co [Complications]
Odds Ratio
Oxycodone/ae [Adverse Effects]
*Pain/dt [Drug Therapy]
Pain/et [Etiology]
Pain Management
Predictive Value of Tests
Retrospective Studies
Young Adult
0 (Analgesics, Opioid)
76I7G6D29C (Morphine)
CD35PMG570 (Oxycodone)
UF599785JZ (Fentanyl)
Types of evidence: 
Type D
Priorities of Care: 
Priority 5: Plan and do